Scrape on a schedule.
Run every few minutes, daily or only on the days you choose.
Learn moreGet each trial's condition, phase, status, sponsor and start date in one sheet that stays current.
Track the clinical trials for a condition by phase and recruiting status.
| Trial | Trial number | Condition | Phase | Status | Sponsor | Start date | Enrollment |
|---|---|---|---|---|---|---|---|
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs | NCT06671587 | Type 2 Diabetes (T2D) | Phase 4 | Recruiting | Sanofi | 2024-12-10 | 678 |
| GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | NCT07314684 | T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Federico II University | 2025-09-08 | 80 |
| Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease | NCT06727409 | Patients With Type 2 Diabetes | Phase 4 | Recruiting | Chinese University of Hong Kong | 2024-12-12 | 82 |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | NCT07244003 | T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-03-29 | 430 |
| The EMPA-FIT Study | NCT06846411 | Diabetes; Diabetes Mellitus, Type II | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 2024-01-01 | 46 |
| The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus | NCT07771010 | Diabetes Type 2 | Phase 4 | Recruiting | University Medical Centre Ljubljana | 2026-04-16 | 54 |
| Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus | NCT05028140 | Type II Diabetes | Phase 3 | Recruiting | EMS | 2024-10-08 | 480 |
| Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus | NCT07552389 | Hypertension; Diabete Type 2 | Phase 3 | Recruiting | Hanlim Pharm. Co., Ltd. | 2025-12-18 | 228 |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | NCT07282743 | Type II Diabetes Mellitus | Phase 2 | Recruiting | Sun Pharmaceutical Industries Limited | 2026-01-20 | 285 |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | NCT07340320 | Type II Diabetes Mellitus | Phase 2 | Recruiting | Corxel Pharmaceuticals | 2026-02-06 | 240 |
| A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | NCT07748208 | Breast Cancer; Diabetes Type II | Phase 2 | Recruiting | Hoffmann-La Roche | 2026-10-30 | 40 |
| Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) | NCT07029009 | Maturity Onset Diabetes of the Young | Phase 2 | Recruiting | Mansa | 2025-05-08 | 50 |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | NCT07385547 | Type II Diabetes Mellitus | Phase 1 | Recruiting | Sun Pharmaceutical Industries Limited | 2026-02-25 | 40 |
| Bioequivalence Study of GZR18 Injection Before and After CMC Change | NCT07355738 | Obesity&T2D | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 2026-01-09 | 138 |
| Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus | NCT05268237 | Diabete Type 2 | Phase 1, Phase 2 | Recruiting | Biolingus | 2023-04-25 | 15 |
| Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | NCT07563699 | Diabete Type 2 | Phase 1, Phase 2 | Recruiting | Mapi Pharma Ltd. | 2026-08-09 | 24 |
| Effects of Core Strengthening Exercises With Diapgragmatic Breathing Versus Core Strengthening Exercises With Pilate Breathing in Diabetes Type II Patients | NCT07290231 | Diabetes Type II | Not Applicable | Recruiting | Foundation University Islamabad | 2025-08-06 | 56 |
| A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients With Type 2 Diabetes | NCT06864546 | Type 2 Diabetes Mellitus, Non Insulin Dependent | Not Applicable | Recruiting | Enea Parimbelli | 2025-05 | 20 |
| Feasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors | NCT06570057 | Type II Diabetes Mellitus | Not Applicable | Recruiting | Baqai Institute of Diabetology and Endocrinology | 2024-06-24 | 240 |
| Culturally Tailored Program for Food-Insecure Adults: SPICE-D | NCT07361341 | Type 2 Diabetes Mellitus (T2D) | Not Applicable | Recruiting | Wake Forest University Health Sciences | 2026-04-01 | 25 |
| Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors | NCT07350694 | Diabetes Type 2; Type II Diabetes Mellitus | Not Applicable | Recruiting | HealthNet Transcultural Psychosocial Organization | 2024-12-24 | 250 |
| Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial | NCT07656805 | T2DM (Type 2 Diabetes Mellitus) | Not Applicable | Recruiting | Anhui Medical University | 2026-06-03 | 88 |
| Assessment of Personalized Follow-up in Prevention of Type 2 Diabetes | NCT05325710 | Diabete Type 2 | Not Applicable | Recruiting | GCS Ramsay Santé pour l'Enseignement et la Recherche | 2022-03-20 | 230 |
| Effect of Diode Laser, Gudmar and Vinegar in Diabetic Patients During Root Canal Treatment | NCT07549373 | Diabete Type 2 | Not Applicable | Recruiting | Sharda University | 2026-05-01 | 90 |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes | NCT07580638 | T2DM (Type 2 Diabetes Mellitus) | – | Recruiting | Chipscreen Biosciences, Ltd. | 2026-09-04 | 3550 |
Download, pull via API, sync to Google Sheets, or send to any app, webhook and data store.
Line up every trial for a condition by phase, sponsor and status.
Know when a sponsor registers or starts a new study.
Keep each run so you can see when a trial starts recruiting or completes.
Get the fields you need from every trial page without copying them one by one.
Run every few minutes, daily or only on the days you choose.
Learn moreRun it again and only new listings are added, with nothing saved twice.
Learn moreAdd one search per city or category and a single recipe runs them all.
Learn moreAdd every product, profile or company page you want and one recipe runs them all.
Learn moreAsk a question about every listing and get the answer as a new column.
Learn moreRows go straight to Google Sheets, Airtable, Zapier, a webhook or the API.
Search a public trial registry for a condition, a drug or a sponsor.
In the Chrome extension or the dashboard, select one trial and pick its title, number, status, condition and sponsor.
Collect the phase, start date and enrollment from each trial's own page.
Schedule the search so new trials and status changes reach your sheet on their own.
Send each run to Google Sheets, Airtable or a webhook, where your team already works.
Create a reusable scraper for any trial registry or public health register.
Build it yourselfSend us the conditions and registries you follow and we'll deliver the trials as a spreadsheet every week.
Get in touchAny public registry that lists its records on web pages: trial registries, licensed facility registers, accredited laboratory lists and published health decisions.
Yes. Simplescraper can open each trial's own page and read its phase, dates, enrollment and eligibility into the same row.
Yes. Schedule the recipe and every run keeps its results, so you can see when a trial starts recruiting or completes.
Yes. Add one search per condition and a single recipe runs them all into the same sheet.
No. Select one trial and Simplescraper reads the same fields from every other trial in the results.
No. Simplescraper collects what a registry publishes about each trial. Whether a trial fits a patient is a decision for their care team.